Observational studyBreast cancer research : BCR2020

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.

Florian Clatot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.